RT Journal Article
SR Electronic
T1 Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.07.22277360
DO 10.1101/2022.07.07.22277360
A1 Shaikh, Yahya
A1 Gupta, Ishaan
A1 Purekal, Sophia
A1 Vaeth, Mary Jane E.
A1 Foyez, Maisha
A1 Callahan, Charles D.
A1 Elhabashy, Maryam
A1 Ficke, James R.
A1 Wu, Albert W.
A1 Auwaerter, Paul G.
A1 Kantsiper, Melinda E.
A1 Siddiqui, Zishan K.
YR 2022
UL http://medrxiv.org/content/early/2022/07/07/2022.07.07.22277360.abstract
AB Background and Methods We conducted a single center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021 and May 14, 2021.Results Among the 2,406 eligible participants, African Americans were significantly more likely to underutilize mAb treatment (OR 1.8; 95% CI 1.5-2.1) and miss treatment opportunities due to monoclonal hesitancy (OR 1.7, 95% CI 1.3-2.1).Conclusion Addressing racial disparities in mAb delivery is an opportunity to bridge the racial inequities in COVID-19 care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Johns hopkins Medicine Institutional review board approved the study, IRB00273988I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not available.